Loading…
Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network
Fertility preservation is not only important for malignant diseases but should also be offered to patients with autoimmune diseases (AID) like vasculitides, prior to cyclophosphamide therapy. No recommendations are available for patients with AID. Analysis from the Fertiprotekt registry of all femal...
Saved in:
| Published in: | Clinical and experimental rheumatology 2012-01, Vol.30 (1 Suppl 70), p.S53-S56 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | S56 |
| container_issue | 1 Suppl 70 |
| container_start_page | S53 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 30 |
| creator | Henes, Joerg C Henes, Melanie von Wolff, Michael Schmalzing, Marc Kötter, Ina Lawrenz, Barbara |
| description | Fertility preservation is not only important for malignant diseases but should also be offered to patients with autoimmune diseases (AID) like vasculitides, prior to cyclophosphamide therapy. No recommendations are available for patients with AID.
Analysis from the Fertiprotekt registry of all female patients with age |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1028016899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1028016899</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-6782af7361c8d554858c754d3c4973ea7398269a080b8fea89b3cbdd639b7ca23</originalsourceid><addsrcrecordid>eNo1kLtOwzAYRj2AaCm8AvLIEsmx4xsbqlqoqFSEgoRYIsf5oxpyw3Za-vZUUJbvLEdn-M7QlDBNE8XF2wRdhvBBCBVcyAs0oZSnVCkxRe9L8NE1Lh7w4CGA35no-g67Du_7Fo7r4hbvTLDjUXLhDsP3AN5BZyHg2vctjlvAv5Xnl02-eMpxB3Hf-88rdF6bJsD1iTP0ulzk88dkvXlYze_XyUDTNCZCKmpqyURqVcV5priykmcVs5mWDIxkWlGhDVGkVDUYpUtmy6oSTJfSGspm6PavO_j-a4QQi9YFC01jOujHUKSEKpIKpfVRvTmpY9lCVQzetcYfiv8_2A8pplwF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1028016899</pqid></control><display><type>article</type><title>Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network</title><source>Freely Accessible Journals</source><creator>Henes, Joerg C ; Henes, Melanie ; von Wolff, Michael ; Schmalzing, Marc ; Kötter, Ina ; Lawrenz, Barbara</creator><creatorcontrib>Henes, Joerg C ; Henes, Melanie ; von Wolff, Michael ; Schmalzing, Marc ; Kötter, Ina ; Lawrenz, Barbara</creatorcontrib><description>Fertility preservation is not only important for malignant diseases but should also be offered to patients with autoimmune diseases (AID) like vasculitides, prior to cyclophosphamide therapy. No recommendations are available for patients with AID.
Analysis from the Fertiprotekt registry of all female patients with age <40 and the diagnosis of a vasculitis. The number of counselled patients, their diagnosis and age, the number of children before the start of therapy as well as the fertility preservation treatment chosen were evaluated.
From January 2007 to November 2011, 47 patients with the diagnosis AID were counselled at 17 of the 69 Fertiprotekt centres. 80.9% decided for at least one of the offered preservation methods. Ovarian cryopreservation was performed in 6 patients, 36 patients opted for GnRH-analogue treatment. Two patients decided for a stimulation therapy for cryopreservation of oocytes.
Regarding the experiences from the registry and the literature gonadotropin releasing hormone analogues are evaluated best and recommended to most of the patients with AID. Cryoconservation of ovarian tissue is a promising option. Stimulation for oocyte cryopreservation can be offered to patients with vasculitis. A combination of the methods might have the biggest preservative effect.</description><identifier>ISSN: 0392-856X</identifier><identifier>PMID: 22512886</identifier><language>eng</language><publisher>Italy</publisher><subject>Adult ; Counseling ; Cryopreservation ; Cyclophosphamide - adverse effects ; Europe ; Female ; Fertility - drug effects ; Fertility Agents, Female - therapeutic use ; Fertility Preservation - methods ; Gonadotropin-Releasing Hormone - analogs & derivatives ; Gonadotropin-Releasing Hormone - therapeutic use ; Humans ; Immunosuppressive Agents - adverse effects ; Infertility, Female - chemically induced ; Infertility, Female - physiopathology ; Infertility, Female - therapy ; Ovary - transplantation ; Ovulation Induction ; Parity ; Pregnancy ; Registries ; Vasculitis - drug therapy ; Vasculitis - physiopathology ; Young Adult</subject><ispartof>Clinical and experimental rheumatology, 2012-01, Vol.30 (1 Suppl 70), p.S53-S56</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22512886$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Henes, Joerg C</creatorcontrib><creatorcontrib>Henes, Melanie</creatorcontrib><creatorcontrib>von Wolff, Michael</creatorcontrib><creatorcontrib>Schmalzing, Marc</creatorcontrib><creatorcontrib>Kötter, Ina</creatorcontrib><creatorcontrib>Lawrenz, Barbara</creatorcontrib><title>Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>Fertility preservation is not only important for malignant diseases but should also be offered to patients with autoimmune diseases (AID) like vasculitides, prior to cyclophosphamide therapy. No recommendations are available for patients with AID.
Analysis from the Fertiprotekt registry of all female patients with age <40 and the diagnosis of a vasculitis. The number of counselled patients, their diagnosis and age, the number of children before the start of therapy as well as the fertility preservation treatment chosen were evaluated.
From January 2007 to November 2011, 47 patients with the diagnosis AID were counselled at 17 of the 69 Fertiprotekt centres. 80.9% decided for at least one of the offered preservation methods. Ovarian cryopreservation was performed in 6 patients, 36 patients opted for GnRH-analogue treatment. Two patients decided for a stimulation therapy for cryopreservation of oocytes.
Regarding the experiences from the registry and the literature gonadotropin releasing hormone analogues are evaluated best and recommended to most of the patients with AID. Cryoconservation of ovarian tissue is a promising option. Stimulation for oocyte cryopreservation can be offered to patients with vasculitis. A combination of the methods might have the biggest preservative effect.</description><subject>Adult</subject><subject>Counseling</subject><subject>Cryopreservation</subject><subject>Cyclophosphamide - adverse effects</subject><subject>Europe</subject><subject>Female</subject><subject>Fertility - drug effects</subject><subject>Fertility Agents, Female - therapeutic use</subject><subject>Fertility Preservation - methods</subject><subject>Gonadotropin-Releasing Hormone - analogs & derivatives</subject><subject>Gonadotropin-Releasing Hormone - therapeutic use</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Infertility, Female - chemically induced</subject><subject>Infertility, Female - physiopathology</subject><subject>Infertility, Female - therapy</subject><subject>Ovary - transplantation</subject><subject>Ovulation Induction</subject><subject>Parity</subject><subject>Pregnancy</subject><subject>Registries</subject><subject>Vasculitis - drug therapy</subject><subject>Vasculitis - physiopathology</subject><subject>Young Adult</subject><issn>0392-856X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNo1kLtOwzAYRj2AaCm8AvLIEsmx4xsbqlqoqFSEgoRYIsf5oxpyw3Za-vZUUJbvLEdn-M7QlDBNE8XF2wRdhvBBCBVcyAs0oZSnVCkxRe9L8NE1Lh7w4CGA35no-g67Du_7Fo7r4hbvTLDjUXLhDsP3AN5BZyHg2vctjlvAv5Xnl02-eMpxB3Hf-88rdF6bJsD1iTP0ulzk88dkvXlYze_XyUDTNCZCKmpqyURqVcV5priykmcVs5mWDIxkWlGhDVGkVDUYpUtmy6oSTJfSGspm6PavO_j-a4QQi9YFC01jOujHUKSEKpIKpfVRvTmpY9lCVQzetcYfiv8_2A8pplwF</recordid><startdate>201201</startdate><enddate>201201</enddate><creator>Henes, Joerg C</creator><creator>Henes, Melanie</creator><creator>von Wolff, Michael</creator><creator>Schmalzing, Marc</creator><creator>Kötter, Ina</creator><creator>Lawrenz, Barbara</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201201</creationdate><title>Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network</title><author>Henes, Joerg C ; Henes, Melanie ; von Wolff, Michael ; Schmalzing, Marc ; Kötter, Ina ; Lawrenz, Barbara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-6782af7361c8d554858c754d3c4973ea7398269a080b8fea89b3cbdd639b7ca23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Counseling</topic><topic>Cryopreservation</topic><topic>Cyclophosphamide - adverse effects</topic><topic>Europe</topic><topic>Female</topic><topic>Fertility - drug effects</topic><topic>Fertility Agents, Female - therapeutic use</topic><topic>Fertility Preservation - methods</topic><topic>Gonadotropin-Releasing Hormone - analogs & derivatives</topic><topic>Gonadotropin-Releasing Hormone - therapeutic use</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Infertility, Female - chemically induced</topic><topic>Infertility, Female - physiopathology</topic><topic>Infertility, Female - therapy</topic><topic>Ovary - transplantation</topic><topic>Ovulation Induction</topic><topic>Parity</topic><topic>Pregnancy</topic><topic>Registries</topic><topic>Vasculitis - drug therapy</topic><topic>Vasculitis - physiopathology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Henes, Joerg C</creatorcontrib><creatorcontrib>Henes, Melanie</creatorcontrib><creatorcontrib>von Wolff, Michael</creatorcontrib><creatorcontrib>Schmalzing, Marc</creatorcontrib><creatorcontrib>Kötter, Ina</creatorcontrib><creatorcontrib>Lawrenz, Barbara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Henes, Joerg C</au><au>Henes, Melanie</au><au>von Wolff, Michael</au><au>Schmalzing, Marc</au><au>Kötter, Ina</au><au>Lawrenz, Barbara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2012-01</date><risdate>2012</risdate><volume>30</volume><issue>1 Suppl 70</issue><spage>S53</spage><epage>S56</epage><pages>S53-S56</pages><issn>0392-856X</issn><abstract>Fertility preservation is not only important for malignant diseases but should also be offered to patients with autoimmune diseases (AID) like vasculitides, prior to cyclophosphamide therapy. No recommendations are available for patients with AID.
Analysis from the Fertiprotekt registry of all female patients with age <40 and the diagnosis of a vasculitis. The number of counselled patients, their diagnosis and age, the number of children before the start of therapy as well as the fertility preservation treatment chosen were evaluated.
From January 2007 to November 2011, 47 patients with the diagnosis AID were counselled at 17 of the 69 Fertiprotekt centres. 80.9% decided for at least one of the offered preservation methods. Ovarian cryopreservation was performed in 6 patients, 36 patients opted for GnRH-analogue treatment. Two patients decided for a stimulation therapy for cryopreservation of oocytes.
Regarding the experiences from the registry and the literature gonadotropin releasing hormone analogues are evaluated best and recommended to most of the patients with AID. Cryoconservation of ovarian tissue is a promising option. Stimulation for oocyte cryopreservation can be offered to patients with vasculitis. A combination of the methods might have the biggest preservative effect.</abstract><cop>Italy</cop><pmid>22512886</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2012-01, Vol.30 (1 Suppl 70), p.S53-S56 |
| issn | 0392-856X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1028016899 |
| source | Freely Accessible Journals |
| subjects | Adult Counseling Cryopreservation Cyclophosphamide - adverse effects Europe Female Fertility - drug effects Fertility Agents, Female - therapeutic use Fertility Preservation - methods Gonadotropin-Releasing Hormone - analogs & derivatives Gonadotropin-Releasing Hormone - therapeutic use Humans Immunosuppressive Agents - adverse effects Infertility, Female - chemically induced Infertility, Female - physiopathology Infertility, Female - therapy Ovary - transplantation Ovulation Induction Parity Pregnancy Registries Vasculitis - drug therapy Vasculitis - physiopathology Young Adult |
| title | Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T16%3A16%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fertility%20preservation%20in%20women%20with%20vasculitis:%20experiences%20from%20the%20FertiPROTEKT%20network&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Henes,%20Joerg%20C&rft.date=2012-01&rft.volume=30&rft.issue=1%20Suppl%2070&rft.spage=S53&rft.epage=S56&rft.pages=S53-S56&rft.issn=0392-856X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1028016899%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p211t-6782af7361c8d554858c754d3c4973ea7398269a080b8fea89b3cbdd639b7ca23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1028016899&rft_id=info:pmid/22512886&rfr_iscdi=true |